SOURCE: ONE Bio, Corp.

January 13, 2010 08:30 ET

ONE Bio Announces Appointments to Independent Board of Directors

Board Strengthened by Diverse, International Additions

MIAMI, FL--(Marketwire - January 13, 2010) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced today that it has bolstered its Board through the appointment of four independent directors: Professor Qingsheng Fan, Mr. James Fernandes, MBA, CPA, CFA, Mr. Jan Koe and Mr. Frank Klees.

"I am very pleased with our new board appointments. With our new and current board members, we have assembled a diverse leadership team with broad experience spanning finance, research, M&A and international business," stated ONE Bio's CEO, Marius Silvasan. "We're confident that this experience will prove valuable in steering ONE Bio on the path towards becoming the preeminent supplier of health supplements and products using green manufacturing processes."

With the appointment of its independent directors ONE Bio has also formalized the members of its key committees: a) corporate governance, b) compensation and c) audit.

ONE Bio (newly appointed) Board Members:

Professor Qingsheng Fan

Mr. Fan is a prominent researcher specializing in Traditional Chinese Medicine, Organic and nutrition & health food specialty research. Mr. Fan's research expertise includes R&D for health food primarily in the area of preparation of healthy products derived from various natural plants. Mr. Fan has published 18 books and more than 60 papers in periodicals in China and abroad. As Chief Editor, Mr. Fan edited the first systematic practical series of books in China on the subject of health food according to new health food registration management measure. For the past 10 years, Mr. Fan has been a Professor and Fellow at the Education Ministry's Food Science Key Laboratory at Nanchang University. Mr. Fan has led 8 national and provincial appraised research projects, and has presided over more than 200 health food project appraisals by the National Food and Drug Supervising Administration of China. Many of these projects have been put into production throughout China and have yielded notable financial benefits to more than 40 different companies. Prior to that Mr. Fan worked as a senior visiting researcher at Pennsylvania State University, studying the anti-cancer effects of certain types of food. Earlier in his career Mr. Fan worked for the Central Laboratory at Jiangxi College of Traditional Chinese Medicine where he pursued his master's degree in immunity pharmacology at the Shanxi College of Traditional Chinese Medicine. Prior to earning his Master's degree, Mr. Fan graduated from the Jiangxi College of Traditional Chinese Medicine. ONE Bio's competitive advantage comes from its strong R&D programs. Mr. Fan's specialty research background and industry experience along with his international accreditations are valuable assets to the ONE Bio team.

James Fernandes, MBA, CPA, CFA

Mr. Fernandes is an experienced banker, fund manager and accounting professional. Mr. Fernandes is an active private investor in a diversified portfolio of private and publicly traded companies. Mr. Fernandes is currently the Chairman and President of Solana Capital Solutions, a provider of growth financing for privately held companies in the retail, industrial, and consumer services sectors. Previously, Mr. Fernandes was a senior equity analyst and investment manager with Lazard Asset Management from 2007 to 2009 and Allianz Global Investors from 2005-2007 and Independence Investments LLC from 2002-2005. Prior to Independence Investments, Mr. Fernandes provided financial advisory services for privately held companies at Devland Financial. Mr. Fernandes started his investment management career with TD Asset Management, the investment management division of one of Canada's largest banks, TD Bank, in 1996. Mr. Fernandes holds a bachelor's degree in accounting from York University and an MBA from Cornell University's Johnson Graduate School of Management (2002). He is also a Certified Public Accountant and Chartered Financial Analyst. Mr. Fernandes was also appointed as chair of ONE Bio's audit committee.

Jan Koe

Mr. Koe, Director, is a seasoned investor and principal in several US based private and publicly traded companies. Mr. Koe's investments cover firms invested in real estate, bioengineering and construction. Mr. Koe is a principal of Method K Partners, Inc., a commercial real estate firm located in Arlington Heights, Illinois which he founded in 1988. Mr. Koe has 30 years of experience in consulting, asset management, leasing and development working with many national real estate firms including Golub & Co., Draper & Kramer Co., Rauch & Co. and Manufacturers Real Estate, a wholly owned affiliate of Manufactures Life Insurance Company. Amongst other assignments Mr. Koe's currently provides a variety of real estate services to the medical industry including serving as a real estate consultant for prominent Chicago area medical institutions. Mr. Koe is also a principal in Chicago-based Paving Solutions LLC. Mr. Koe holds a Bachelors degree in Business Administration and Psychology from Luther College in Decorah, Iowa. Mr. Koe's business acumen and experience in real estate are valuable assets to ONE as it grows its manufacturing capacity and real estate footprint to service the worldwide demand for its products. Mr. Koe was also appointed as chair of ONE Bio's compensation committee.

Frank Klees

Mr. Klees is an accomplished business man, a highly regarded and influential politician and active member of the board of several publicly traded corporations. Mr. Klees, during his career, has developed a strong base of contacts throughout the Asia Pacific region. Mr. Klees currently sits on the corporate boards of a number of companies including Roxul Inc., Northern Ethanol Inc., Tribute Resources, and National Medical Imaging. In 1990, Mr. Klees co-founded the Municipal Gas Corporation where he served as the company's Executive Vice President with responsibilities for business development and government relations. Mr. Klees began his business career in financial services in 1974 with the Canada Life Assurance Company, headquartered in Toronto, Canada. Mr. Klees further developed a financial services practice which further expanded into contract negotiations and investment advisory services. In June of 1995, Mr. Klees was elected to the Ontario Legislature, where he has served in numerous senior government positions, including Chief Government Whip, Deputy House Leader, Minister of Tourism and Minister of Transportation. He is currently the Official Opposition Critic for the Ministry of Transportation and the Ministry of Public Infrastructure Renewal. During Mr. Klees' 15 years of government service, Mr. Klees developed numerous relationships in the Asia Pacific in multiple areas. Mr. Klees currently provides advisory services to public and private companies, drawing from his extensive business, administration and government experiences. Mr. Klees' extensive and diverse business and public experience combined with his unusually large network of contacts makes Mr. Klees a tremendous asset to our company. Mr. Klees was also appointed as chair of ONE Bio's corporate governance and nomination committee.

About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) ( headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information